Derazantinib (ARQ-087) is primarily used in the treatment of certain types of cancer, particularly those involving fibroblast growth factor receptor (FGFR) genetic alterations. It is a selective FGFR inhibitor, which makes it effective in targeting cancers driven by FGFR pathway dysregulation.

One of its key applications is in the treatment of intrahepatic cholangiocarcinoma, a rare form of bile duct cancer, especially in patients with FGFR2 fusion mutations. By inhibiting FGFR signaling, Derazantinib helps to slow down tumor growth and progression in these cases.

Additionally, it is being investigated for use in other FGFR-driven cancers, such as bladder cancer, gastric cancer, and breast cancer, where FGFR abnormalities are implicated. Its ability to specifically target FGFR makes it a promising therapeutic option for precision medicine in oncology, offering potential benefits for patients with limited treatment alternatives.